Moderate Alcohol Consumption, Risk of Cardiovascular Disease and Type 2 Diabetes: Influence of Alcohol Oxidation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00285909|
Recruitment Status : Completed
First Posted : February 2, 2006
Last Update Posted : August 16, 2006
Moderate alcohol consumption is associated with a decreased risk of cardiovascular disease and type 2 diabetes. The association of alcohol consumption with cardiovascular disease is mediated by a functional polymorphism of alcohol dehydrogenase 1c, but the effect of this polymorphism on alcohol metabolism is only investigated in vitro.
The risk reduction of moderate alcohol consumption for cardiovascular disease is explained largely by an increase of HDL cholesterol, but an increase of adiponectin concentrations after moderate alcohol consumption may also be involved. It seems likely that adiponectin is a mediator for the association of moderate alcohol consumption with type 2 diabetes. The mechanism by which moderate alcohol consumption increases adiponectin concentrations is unknown, but ppar-gamma activation may be involved.
effects of this polymorphism on mediators of this relation are not known. This study therefore investigates the effect of moderate alcohol consumption and the influence of alcohol dehydrogenase 1c polymorphism on ppar-gamma activated gene expression and risk factors of cardiovascular disease and type 2 diabetes.
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Disease Type 2 Diabetes||Behavioral: Alcohol: 25 gday (white wine)||Not Applicable|
To investigate the effect of moderate alcohol consumption and influence of genetic variation of ethanol oxidation on:
- PPAR-γ activated gene expression
- Markers of coronary heart disease or type 2 diabetes
- Postprandial changes of HPA-axis activity among 36 postmenopausal women with ADH1C genotype associated with slow or fast alcohol metabolism.
Design : Randomized, controlled, not blinded crossover trial with 1 week wash-out preceding each treatment period
- Description : Apparently healthy postmenopausal women
- Number : 36
- Test substance : White wine (ca. 25 g alcohol/day)
- Reference substance : White grape juice
Study treatments Treatment A: 250 ml white wine daily (ca. 25 g alcohol/day) Treatment B: 250 ml white grape juice daily
- Duration : two periods of 6 weeks preceded by 1 week wash-out period
- Adiponectin mRNA expression
- Expression of PPAR-gamma activated genes: CD36, lipoprotein lipase, AP2
- Markers of cardiovascular disease (blood lipid profile, Lp-PLA2 activity, hs-CRP, fibrinogen)
- Markers of type 2 diabetes (adiponectin, adiponectin oligomers, insulin sensitivity)
- Parameters of alcohol oxidation (postprandial: blood alcohol and acetate, acetaldehyde)
- HPA-axis activity (postprandial & fasting: cortisol, ACTH, testosterone)
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||36 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Moderate Alcohol Consumption on PPAR-γ Activity and Risk Markers of Metabolic Disease: Influence of Genetic Variation in Alcohol Oxidation|
|Study Start Date :||March 2006|
|Study Completion Date :||June 2006|
- PPAR-gamma activated gene expression
- Risk factors of cardiovascular disease and type 2 diabetes
- Postprandial changes of HPA-axis activity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00285909
|Principal Investigator:||Henk FJ Hendriks, PhD.||TNO|